Thrombin inhibitors identified by computer-assisted multiparameter design.

Here, we present a series of thrombin inhibitors that were generated by using powerful computer-assisted multiparameter optimization process. The process was organized in design cycles, starting with a set of randomly chosen molecules. Each cycle combined combinatorial synthesis, multiparameter characterization of compounds in a variety of bioassays, and algorithmic processing of the data to devise a set of compounds to be synthesized in the next cycle. The identified lead compounds exhibited thrombin inhibitory constants in the lower nanomolar range. They are by far the most selective synthetic thrombin inhibitors, with selectivities of >100,000-fold toward other proteases such as Factor Xa, Factor XIIa, urokinase, plasmin, and Plasma kallikrein. Furthermore, these compounds exhibit a favorable profile, comprising nontoxicity, high metabolic stability, low serum protein binding, good solubility, high anticoagulant activity, and a slow and exclusively renal elimination from the circulation in a rat model. Finally, x-ray crystallographic analysis of a thrombin-inhibitor complex revealed a binding mode with a neutral moiety in the S1 pocket of thrombin.

[1]  Mary L. Westbrook,et al.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. , 1991 .

[2]  Barry Robson,et al.  PRO_LIGAND: An approach to de novo molecular design. 3. A genetic algorithm for structure refinement , 1995, J. Comput. Aided Mol. Des..

[3]  Y. Tsuda,et al.  Development of plasma kallikrein selective inhibitors. , 1992, Biopolymers.

[4]  Andreas Schwienhorst,et al.  Genetic algorithm for the design of molecules with desired properties , 2002, J. Comput. Aided Mol. Des..

[5]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[6]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[7]  Sean T. Quinn,et al.  Automated Assay Optimization with Integrated Statistics and Smart Robotics , 2000, Journal of biomolecular screening.

[8]  J. Stürzebecher,et al.  Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. , 1999, Thrombosis research.

[9]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[10]  J. Stürzebecher,et al.  Influence of Structural Variations in Peptidomimetic 4-Amidinophenylalanine-Derived Thrombin Inhibitors on Plasma Clearance and Biliary Excretion in Rats , 2002, Pharmaceutical Research.

[11]  T. Steinmetzer,et al.  Structure-Activity Relationships of New NAPAP-Analogs , 2001, Journal of enzyme inhibition and medicinal chemistry.

[12]  Petra Schneider,et al.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..

[13]  T. Steinmetzer,et al.  Advances in the development of thrombin inhibitors , 2001, Expert opinion on investigational drugs.

[14]  W. Schumacher,et al.  Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis. , 1994, European journal of pharmacology.

[15]  G Klebe,et al.  Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. , 2001, Journal of molecular biology.

[16]  S. Gardell,et al.  Assessment of Thrombin Inhibitor Efficacy in a Novel Rabbit Model of Simultaneous Arterial and Venous Thrombosis , 1998, Thrombosis and Haemostasis.

[17]  W. Schumacher,et al.  Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. , 1996, Journal of cardiovascular pharmacology.

[18]  S. Pehrsson,et al.  Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.